Q-omics provides the consensus-scored PRAL profile across patient tissues and cancer cell-line models. PRAL expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, PRAL is differentially expressed in 8, with the highest sampling consensus in HNSC. Additionally, PRAL RNA expression shows 16,206 significant gene co-expression associations, with the highest sampling consensus in DLBC. Together, these results highlight KIRC, HNSC, and DLBC as cancer lineages where PRAL shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PRAL — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PRAL survival associations across molecular data types. PRAL RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PRAL RNA expression–survival associations across cancer types. High PRAL expression shows unfavorable associations in KIRC, UCEC, KIRP and LGG, but favorable associations in SKCM and BLCA. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for PRAL RNA expression.
This table summarizes PRAL tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for PRAL. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PRAL shows lower tumor expression in KICH and UCEC and higher tumor expression in HNSC, BLCA, KIRC and BRCA. The HNSC box plot shows higher PRAL RNA expression in tumor versus normal tissue (log2 FC = +0.216, t-test p < 0.001).
This table shows molecular features associated with PRAL in patient tissues and cancer cell lines. In patient samples, PRAL shows the broadest associations at the RNA and protein expression levels, with DLBC recurring as the lineage with the largest associated feature set.
